The UPMC Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory (IMCPL) is a unique facility designed to effectively support the investigators of UPMC Hillman who are pursuing cellular therapies, viral products and immune modulation under two categories: manufacturing products for cellular therapy studies under Investigational New Drug (IND) and developing and using assays for serial monitoring of immunologic functions in patients with cancers who have been treated with biologic therapies in clinical trials.
An NCI-designated Comprehensive Cancer Center, affiliated with the University of Pittsburgh School of Medicine
Research
